{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:39:09Z","timestamp":1790775549406,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jbspin.2025.105854","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T17:50:33Z","timestamp":1739901033000},"page":"105854","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["bDMARD drug survival in combination therapy with methotrexate in psoriatic arthritis: A systematic literature review and meta-analysis"],"prefix":"10.1016","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5139-8471","authenticated-orcid":false,"given":"S\u00e9lina","family":"Hanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiphaine","family":"Dujardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gaudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athan","family":"Baillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Romand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2025.105854_bib0260","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2025.105854_bib0265","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jbspin.2025.105854_bib0270","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u00a0\u2013\u00a0Part 1: treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jbspin.2025.105854_bib0275","doi-asserted-by":"crossref","first-page":"105469","DOI":"10.1016\/j.jbspin.2022.105469","article-title":"The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: similarities and differences","volume":"90","author":"Coates","year":"2023","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2025.105854_bib0280","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105854_bib0285","first-page":"CD012722","article-title":"Methotrexate for psoriatic arthritis","volume":"1","author":"Wilsdon","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jbspin.2025.105854_bib0290","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221092376","article-title":"Is there still a place for methotrexate in severe psoriatic arthritis?","volume":"14","author":"Felten","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jbspin.2025.105854_bib0295","doi-asserted-by":"crossref","first-page":"e002883","DOI":"10.1136\/rmdopen-2022-002883","article-title":"Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis: an observational nationwide study","volume":"9","author":"Lindstr\u00f6m","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2025.105854_bib0300","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1016\/S2665-9913(22)00008-X","article-title":"Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study","volume":"4","author":"Coates","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105854_bib0305","doi-asserted-by":"crossref","first-page":"e003423","DOI":"10.1136\/rmdopen-2023-003423","article-title":"Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis","volume":"10","author":"Mease","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2025.105854_bib0310","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/rheumatology\/keu415","article-title":"Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature","volume":"54","author":"Behrens","year":"2015","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2025.105854_bib0315","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1093\/rheumatology\/kez671","article-title":"Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register","volume":"59","author":"Bechman","year":"2020","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2025.105854_bib0320","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/annrheumdis-2020-217725","article-title":"Methotrexate reduces withdrawal rates of TNF inhibitors due to ineffectiveness in rheumatoid arthritis but only in patients who are seropositive","volume":"79","author":"Greenwood","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105854_bib0325","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","article-title":"Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"45","author":"Hyrich","year":"2006","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2025.105854_bib0330","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1136\/annrheumdis-2020-219499","article-title":"Methotrexate prolongs TNF inhibitor survival, but only in autoantibody-positive rheumatoid arthritis: a validation study","volume":"82","author":"van Mulligen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105854_bib0335","doi-asserted-by":"crossref","first-page":"e14926","DOI":"10.1111\/dth.14926","article-title":"Are biologics combined with methotrexate better than biologics monotherapy in psoriasis and psoriatic arthritis: a meta-analysis of randomized controlled trials","volume":"34","author":"Xie","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jbspin.2025.105854_bib0340","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2025.105854_bib0345","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.jbspin.2025.105854_bib0350","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/annrheumdis-2021-220097","article-title":"Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15,332 patients with psoriatic arthritis. Data from the EuroSpA collaboration","volume":"80","author":"Lindstr\u00f6m","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105854_bib0355","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.30117","article-title":"Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor \u03b1 therapy: results from the nationwide Danish DANBIO registry","volume":"63","author":"Glintborg","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2025.105854_bib0360","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3899\/jrheum.170477","article-title":"Comparative analysis and predictors of 10-year tumor necrosis factor inhibitors drug survival in patients with spondyloarthritis: first-year response predicts long-term drug persistence","volume":"45","author":"Flouri","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105854_bib0365","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3899\/jrheum.190299","article-title":"Comparative persistence of methotrexate and tumor necrosis factor inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"47","author":"George","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105854_bib0370","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.semarthrit.2016.09.005","article-title":"Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: a prospective cohort study","volume":"46","author":"Aaltonen","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2025.105854_bib0375","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.berh.2019.02.012","article-title":"Efficacy and survival of golimumab with and without methotrexate in patients with psoriatic arthritis: a retrospective study from daily clinical practice","volume":"32","author":"Sharif","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105854_bib0380","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/ard.2007.073544","article-title":"Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register","volume":"67","author":"Kristensen","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105854_bib0385","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/acr.23090","article-title":"Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: a multicenter retrospective analysis","volume":"69","author":"Favalli","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2025.105854_bib0390","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1007\/s10067-021-05742-3","article-title":"Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry","volume":"40","author":"Pombo-Suarez","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105854_bib0395","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/acr.23333","article-title":"Impact of comorbidities on tumor necrosis factor inhibitor therapy in psoriatic arthritis: a population-based cohort study","volume":"70","author":"Ballegaard","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2025.105854_bib0400","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/ard-2022-222879","article-title":"Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study","volume":"82","author":"Gossec","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105854_bib0405","doi-asserted-by":"crossref","first-page":"e000596","DOI":"10.1136\/rmdopen-2017-000596","article-title":"Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register","volume":"4","author":"Fagerli","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2025.105854_bib0410","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/ar2670","article-title":"Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register","volume":"11","author":"Saad","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2025.105854_bib0415","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/rheumatology\/kex387","article-title":"Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis","volume":"57","author":"Stober","year":"2018","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2025.105854_bib0420","first-page":"1059","article-title":"Psoriatic arthritis treated by anti-TNFs: a monocentric trial of 102 cases in Auvergne, France","volume":"34","author":"Soubrier","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105854_bib0425","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.23333","article-title":"The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study","volume":"59","author":"Heiberg","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2025.105854_bib0430","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","article-title":"The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study","volume":"73","author":"Fagerli","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105854_bib0435","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13075-021-02417-x","article-title":"Treatment persistence of biologics among patients with psoriatic arthritis","volume":"23","author":"Haddad","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2025.105854_bib0440","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1093\/rheumatology\/keu252","article-title":"Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO","volume":"53","author":"Glintborg","year":"2014","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2025.105854_bib0445","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3899\/jrheum.190815","article-title":"Tumor necrosis factor inhibitor monotherapy versus combination therapy for the treatment of psoriatic arthritis: combined analysis of European biologics databases","volume":"48","author":"Thomas","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105854_bib0450","first-page":"1488","article-title":"Long-term follow-up of anti-infliximab antibodies in patients with radiographic axial spondyloarthritis: a marker of drug survival and tapering","volume":"76","author":"Pimentel","year":"2024","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.jbspin.2025.105854_bib0455","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.jid.2022.01.033","article-title":"Adalimumab with methotrexate vs. adalimumab monotherapy in psoriasis: first-year results of a single-blind randomized controlled trial","volume":"142","author":"van der Kraaij","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jbspin.2025.105854_bib0460","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","article-title":"Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial","volume":"74","author":"Burmester","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105854_bib0465","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3899\/jrheum.140685","article-title":"Prevalence of TNF-\u03b1 blocker immunogenicity in psoriatic arthritis","volume":"42","author":"Zisapel","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105854_bib0470","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s40744-024-00704-y","article-title":"Treatment with targeted therapy in patients with psoriatic arthritis and inadequate response to methotrexate: proposal for a rational strategy","volume":"11","author":"Goupille","year":"2024","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jbspin.2025.105854_bib0475","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/ard.2006.058339","article-title":"Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial","volume":"66","author":"Kavanaugh","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105854_bib0480","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1136\/annrheumdis-2012-202035","article-title":"Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study","volume":"72","author":"Kavanaugh","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105854_bib0485","doi-asserted-by":"crossref","first-page":"e001047","DOI":"10.1136\/rmdopen-2019-001047","article-title":"Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial","volume":"6","author":"Ducourau","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2025.105854_bib0490","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1136\/annrheumdis-2014-205554","article-title":"Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up","volume":"73","author":"Vogelzang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105854_bib0495","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2022-222155","article-title":"EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases","volume":"82","author":"Krieckaert","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105854_bib0500","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3899\/jrheum.190116","article-title":"Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis","volume":"47","author":"Deodhar","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105854_bib0505","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1007\/s10067-022-06218-8","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results","volume":"41","author":"Coates","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105854_bib0510","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1093\/rheumatology\/kead177","article-title":"The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate","volume":"62","author":"Mojtahed Poor","year":"2023","journal-title":"Rheumatol Oxf Engl"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X25000132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X25000132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T17:19:58Z","timestamp":1747847998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X25000132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1297319X25000132"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2025.105854","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"bDMARD drug survival in combination therapy with methotrexate in psoriatic arthritis: A systematic literature review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2025.105854","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\ufffdt\ufffd Fran\ufffdaise de Rhumatologie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105854"}}